ALLMedicine™ Hemolytic Uremic Syndrome Center
Research & Reviews 849 results
Journal of Cardiac Surgery; Ketenciler S, Gemalmaz H et. al.
Jul 27th, 2021 - The treatment of the massive pulmonary embolism concomitant hemodynamic instability in pregnancy is difficult and controversial and carries a high risk for both the baby and the mother. The catheter-directed thrombectomy with or without extracorpo...
Pediatric Neurology; Corgier-Pattberg A, Beylerian M et. al.
Jul 23rd, 2021 - Hemolytic uremic syndrome (HUS) is the most common cause of acute kidney failure in children younger than five years. Central nervous system involvement occurs in 15% of patients, with clinical manifestations including confusion, coma, seizures, s...
Hypertension (Dallas, Tex. : 1979); Burwick RM, Moyle K et. al.
Jul 20th, 2021 - Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory ...
https://doi.org/10.1007/s00467-021-05193-7 10.1007/s00467-009-1137-6 10.1681/ASN.2019040331 10.1097/MOH.0b013e32833cae86 10.1186/1750-1172-6-60 10.1097/MJT.0b013e31829b59dc 10.1055/s-2001-15247 10.1067/mpd.2003.79 10.1038/ng.2590 10.1007/s00467-015-3076-8 10.1007/s00467-014-2817-4 10.1056/NEJMc0809959 10.1542/peds.2011-1685 10.1056/NEJMoa1208981 10.1111/j.1399-3089.2006.00279.x 10.1007/s00467-012-2279-5 10.1097/TP.0000000000001325 10.1182/blood-2018-09-876805 10.1007/s00467-014-2868-6 10.1007/s40265-019-01068-2
Pediatric Nephrology (Berlin, Germany); Stojanovic J, Adamusiak A et. al.
Jul 18th, 2021 - A 3-year-old girl with clinical features of atypical HUS (complement Factor I mutation inherited from an asymptomatic mother and Factor H autoantibodies) was treated with plasma exchange, progressed to kidney failure (KF) aged 4 years, and receive...
The Journal of Pediatrics; Ardissino G, Vignati C et. al.
Jul 2nd, 2021 - To analyze the results of an enhanced laboratory-surveillance protocol for bloody diarrhea aimed at identifying children with Shiga toxin-producing Escherichia coli (STEC) infection early in the course of the disease toward the early identificatio...
Guidelines 4 results
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.
Jul 17th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.
Apr 11th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....
Clinical and Experimental Nephrology; Igarashi T, Ito S et. al.
Aug 8th, 2014 - Guidelines for the management and investigation of hemolytic uremic syndrome.|2014|Igarashi T,Ito S,Sako M,Saitoh A,Hataya H,|standards,diagnosis,etiology,therapy,standards,
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.
Sep 19th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...
Drugs 13 results see all →
Clinicaltrials.gov 16 results
Oct 18th, 2018 - This is a Phase 3, multicenter study of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The uncontrolled, open-label study will evaluate the effect of OMS721 in subjects with plasma therapy-resistant aHUS and plasm...
Oct 11th, 2018 - Background: Shiga toxin-producing Escherichia coli (STEC) cause a spectrum of disease, ranging from asymptomatic carriage to bloody diarrhea and the hemolytic uremic syndrome (HUS). HUS is caused by a toxin that destroys red blood cells, consumes ...
Oct 5th, 2018 - OBJECTIVES: Conduct research for same use of stored human samples, specimens, and data collected from patients previously enrolled in a terminated National Cancer Institute-Institutional Review Board clinical trial. Correlate plasma levels and pha...
Oct 1st, 2018 - The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an important cause of acquired chronic kidney disease in children ....
Sep 3rd, 2018 - This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associat...
News 66 results
Apr 20th, 2020 - (Reuters) - Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome. The study is expec...
Oct 21st, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...
Ayan Nasir*, Nimai Patel* et. al.
Jun 5th, 2019 - Hemolytic uremic syndrome (HUS) is a rare illness that can be acquired through the consumption of food products contaminated with strains of Shiga toxin-producing Escherichia coli (E coli ; STEC). 1 Between 6% and 15% of individuals infected with.
Jun 1st, 2019 - Click here to access June 2019 Management of Neurologic Disorders in Federal Health Care Table of Contents Early and Accurate Identification of Parkinson Disease Among US Veterans Proton Pump Inhibitor Use and Risk of Dementia in the Veteran Popul.
May 4th, 2019 - PHILADELPHIA — Intravenous eculizumab (Soliris, Alexion Pharmaceuticals) significantly decreased risk for relapse in patients with neuromyelitis optical spectrum disorder (NMOSD) over placebo, in a new multicountry phase 3 study. Findings from PRE...